To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
17 Current news
rss
uniQure licenses RNA interference technology to advance Huntington’s disease program
06-12-2012
uniQure B.V. announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. giving uniQure access to Benitec’s proprietary DNA-directed RNA interference (ddRNAi) technology...
Benitec strengthenss Intellectual Property Position in Gene Silencing with more patents granted in Europe and the US
05-05-2011
Benitec Ltd announced that two further patents owned or licensed exclusively by Benitec have been granted or allowed in Europe and the US respectively.The CSIRO-owned patent EP1068311-B1 (“Methods...
Benitec’s Hepatitis B RNAi Program with Biomics Biotechnologies Moves to the Next Stage Following Successful Stage 1 Results
23-02-2011
Benitec Limited announced that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus (HBV), conducted...
Strengthening and Expansion of Benitec’s Patent Position in RNAi
Graham ‘099 Patent Re-Examination Certificate Issued in the US and another Graham Patent granted in a Further European Country
21-02-2011
Benitec Limited announced that the United States Patent and Trademark Office (USPTO) has indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO’s confirmation...
Benitec secures further rights to HIV Therapeutic
Collaboration with City of Hope in HIV trial
30-04-2008
Benitec Limited has secured further intellectual property rights that underpin its HIV/AIDS lymphoma therapeutic currently undergoing clinical trials at City of Hope in Duarte, California...
Sigma-Aldrich Welcomes the University of Edinburgh to the RNAi Partnership Program
06-10-2006
, Benitec and Oxford BioMedica provide Sigma-Aldrich with a major intellectual property portfolio in RNAi. Existing members of the Sigma RNAi Partnership Program include Rutgers University, University...
Benitec appoints new CFO
27-09-2006
The Board of Directors of Benitec Limited announced that the Company had appointed Paul McMahon as the new Chief Financial Officer (CFO) effective immediately. Paul is a CPA and Chartered Secretary...
Sigma-Aldrich Initiates RNAi Partnership Program
26-04-2006
, Oxford BioMedica and Benitec. The partnership program will also facilitate collaborations with scientists at Sigma-Aldrich to validate current and emerging RNAi technologies. Program participants...
Benitec delays IND filing for HIV/AIDS therapeutic pending resolution of manufacturing result
09-02-2006
Benitec Ltd. announced that the Investigational New Drug (IND) filing with the US Food & Drug Administration (FDA) for its HIV/AIDS therapeutic will be delayed. The delay is due to one aberrant...
Benitec grants Sigma-Aldrich license to RNAi patent portfolio
Sigma-Aldrich Acquires Equity Stake in Benitec
27-10-2005
Benitec Ltd. and Sigma-Aldrich Corporation announced the signing of two major agreements, one in which Sigma acquires an equity stake in Benitec and one in which Benitec grants Sigma a license...
Netmeeting
